We are building a pipeline to test and evaluate new medicines based on therapeutic nucleic acids and readying ourselves for a structured approach to clinical trials.
Pre-clinical product development
A comprehensive array of pre-clinical models will be utilised to test therapeutic leads generated by REACT. Existing targets will be fast tracked for safety and efficacy assessment in models of chronic heart failure conditions, and then prioritised for translational development.
Studies will involve:
- Primary cells from neonatal and adult mouse and rat hearts, and human iPS cell-derived cardiomyocytes,
- 3D cardiac tissue models, including human organoids (sometimes known as 'cardioids'), engineered human heart tissue and human living myocardial slices from hearts explanted from patients undergoing heart transplantation,
- Mouse and pig myocardial infarction and heart failure models with longitudinal functional imaging for efficacy assessment.
Clinical studies
We aim to develop new therapeutic products for patients with cardiovascular conditions through a structured approach.
This will include early engagement with regulatory authorities to define studies that would, for example, enable Investigational New Drug applications to the US Food and Drug Administration and Clinical Trial Applications with the European Medicines Agency.
Our clinical studies will also include pilot efficacy studies and observational studies on biodistribution of novel therapies.
Clinical translation projects
Read more about work underway in this challenge area
Collaborate with us
If you have relevant expertise, intellectual property or facilities that could help us tackle this challenge, we want to hear from you.
Contact us by email and our operations team will direct you to members working in this area.